DONG Yafen, WANG Jian, ZHU Wenjun, CUI Qiaoyan, LIU Helong, QIU Yan. Effectiveness analysis of clinical pharmacists intervention in the clinical application of piperacillin-tazobactam based on PDCA[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(6): 574-576. doi: 10.12206/j.issn.1006-0111.202002088
Citation:
|
DONG Yafen, WANG Jian, ZHU Wenjun, CUI Qiaoyan, LIU Helong, QIU Yan. Effectiveness analysis of clinical pharmacists intervention in the clinical application of piperacillin-tazobactam based on PDCA[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(6): 574-576. doi: 10.12206/j.issn.1006-0111.202002088
|
Effectiveness analysis of clinical pharmacists intervention in the clinical application of piperacillin-tazobactam based on PDCA
- Received Date: 2020-02-27
- Rev Recd Date:
2020-09-14
- Publish Date:
2020-11-25
-
Abstract
Objective To explore the effect of the intervention of clinical pharmacists on the rational use of piperacillin-tazobactam by using PDCA cycle, in order to provide reference for rational drug use. Methods The problems of piperacillin-tazobactam in our hospital was analyzed. PDCA cycle was used to manage the problems. Then, the data before and after PDCA cycle was compared and analyzed. Results After using PDCA cycle, the irrational use rate of piperacillin-tazobactam gradually decreased, from 9% in February 2018 to 2% in February 2019; the doses decreased from 4380 in February 2018 to 3346 in February 2019; and the frequency of usage decreased from 391 DDDs in February 2018 to 298 DDDs in February 2019. The effectiveness and continuous improvement of PDCA cycle in managing piperacillin-tazobactam were significant. Conclusion PDCA cycle can effectively improve the management effectiveness of piperacillin-tazobactam administration.
-
References
[1]
|
蓝丽娟, 叶青. 哌拉西林他唑巴坦钠治疗慢性支气管炎的效果观察[J]. 现代实用医学, 2019, 31(12):1630-1632. doi: 10.3969/j.issn.1671-0800.2019.12.034 |
[2]
|
陈刚, 徐永芳, 徐长青, 等. 哌拉西林他唑巴坦联合依替米星治疗支气管扩张患者感染疗效的分析[J]. 中华医院感染学杂志, 2016, 26(9):1970-1972. |
[3]
|
黄琳惠, 黄奕江, 敬攀, 等. 哌拉西林他唑巴坦在重症患者的肺组织渗透性[J]. 中国现代医学杂志, 2017, 27(8):59-63. doi: 10.3969/j.issn.1005-8982.2017.08.013 |
[4]
|
《抗菌药物临床应用指导原则》修订工作组. 《抗菌药物临床应用指导原则》(2015版). 国卫办医发[2015] 43号附件, 2015, 1-87. |
[5]
|
范洪伟. 桑德福 抗微生物治疗指南[M]. 新译本第48版. 北京: 中国协和医科大学出版社, 2019: 17-78. |
[6]
|
JOSHUA P M, GRANT W W, ANN C L, et al. Diagnosis and treatment of adults with community-acquired pneumonia[J]. Am J Respir Crit Care Med,2019,200(7):e45-e67. |
[7]
|
慢性阻塞性肺疾病急性加重诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识[J]. 国际呼吸杂志, 2017, 37(14):1041-1057. doi: 10.3760/cma.j.issn.1673-436X.2017.14.001 |
[8]
|
叶小春, 张耕, 杨春瑜. 某院2016年第四季度丙氨酰谷氨酰胺基于PDCA循环专项点评成效分析[J]. 中南药学, 2017, 15(12):1779-1781. doi: 10.7539/j.issn.1672-2981.2017.12.029 |
[9]
|
李博宇, 崔向丽, 邱爽, 等. 胸腺五肽注射液不合理用药干预分析[J]. 中国临床药理学杂志, 2017, 33(7):653-655. |
-
-
Proportional views
-